Author

Michelle S. Dierker

Observed name: Michelle Dierker

Institutions: Edward Hines, Jr. VA Hospital, John D. Dingell VA Medical Center

Observed institutions: Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Edward Hines, Jr. VA Hospital, Henry Ford Hospital, John D. Dingell VA Medical Center, VA San Diego Healthcare System

ORCID: 0009-0005-3914-4508

Observed ORCID: 0009-0005-3914-4508

OpenAlex ID: A5055797996

Risk Factors for Carbapenem-Resistant Enterobacterales Clinical Treatment Failure

2023 · Nicholas Rebold, Abdalhamid M. Lagnf, et al. · Microbiology Spectrum · 29

Multicenter, retrospective cohort study of antimycobacterial treatment-related harms among patients with non-tuberculosis Mycobacterium infections in the United States

2025 · Michael P. Veve, Rachel M. Kenney, et al. · Antimicrobial Agents and Chemotherapy · 5

Systemic-Sclerosis-Related Interstitial Lung Disease: A Review of the Literature and Recommended Approach for Clinical Pharmacists

2023 · Hannah Marie Ferrari, Pramodini Kale-Pradhan, et al. · Annals of Pharmacotherapy · 4

Four-factor prothrombin complex concentrate for the reversal of apixaban prior to deceased donor kidney transplant: A case series

2026 · Michelle S. Dierker, Anne Przybylski, et al. · Journal of Thrombosis and Thrombolysis · 1

970: Prothrombin Complex Concentrate for Apixaban Reversal Prior to Deceased Donor Kidney Transplant

2025 · Michelle Dierker, Anne Przybylski, et al. · Critical Care Medicine · 1

Apixaban Use Before Kidney Transplantation: Is Reversal Necessary?

2026 · Laura Cotiguala, Anne Przybylski, et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy

Works count: 6

Citation count: 40

H-index: 3

I10-index: 1